Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance

Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have preliminary evidence showing that hyperbaric oxygen therapy rapidly increases insulin sensitivity in humans. This requires confirmation in a larger population, and with this study the investigators will also test for mechanisms how this occurs. The investigators suspect that modulation of hypoxia and stress response proteins following changes in tissue oxygenation may contribute to these improvements. This study has the potential to yield new and important insights into the insulin resistance in obesity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Hypoxia Inflammation Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Respiratory Type 2 Diabetes

Age range

45 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Adelaide

Adelaide, South Australia, Australia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Obese men with and without type 2 diabetes aged 45-70
Lean men without type 2 diabetes aged 45-70

Exclusion criteria

smokers
claustrophobic
sleep apnoea
blood donor
exercise more than 2 times per week
under certain medications eg: bleomycin,corticosteroid

Treatment and study plan

Hyperbaric Oxygen Treatment

Procedure

Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.

Primary outcomes

Insulin sensitivity

Time frame: 1 year

Using Hyperinsulinemic clamp

Secondary outcomes

Hypoxia and inflammatory markers

Time frame: 1 year

using IHC, qPCR, Western blot

Sponsors and collaborators

Lead sponsor

University of Adelaide

Other

Registry information

Acronym: HOTAIR

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: May 27, 2011
Registry last updated: Sep 19, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed